The achievement of a better life for cystic fibrosis (CF) patients is mainly caused by a better management and infection control over the last three decades. Herein, we want to summarize the cornerstones for an effective management of CF patients and to give an overview of the knowledge about the fungal epidemiology in this clinical context in Europe. Data from a retrospective analysis encompassing 66,616 samples from 3235 CF patients followed-up in 9 CF centers from different European countries are shown.

Department of Clinical Microbiology and Immunology The Children's Memorial Health Institute Warsaw Poland

Department of Infectious Diseases Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Department of Laboratories and Diagnostic Immunology Children's Hospital and Research Institute Bambino Gesù Rome Italy

Department of Medical Microbiology Charles University and Motol University Hospital Prague Czech Republic

Department of Pediatric Pneumology and Immunology Cystic Fibrosis Center Berlin Charité Universitätsmedizin Berlin Berlin Germany

Host Pathogen Interaction Study Group UNIV Angers UNIV Brest Université Bretagne Loire Angers France

Institute of Hygiene Microbiology and Environmental Medicine Medical University of Graz Graz Austria

Institute of Medical Microbiology and Hospital Epidemiology Medizinische Hochschule Hannover Carl Neuberg Str 1 30625 Hannover Germany

Institute of Microbiology and Immunology Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Laboratory of Parasitology Mycology Angers University hospital Angers France

Pulmonary Outpatient's Clinic The Children's Memorial Health Institute Warsaw Poland

Servicio de Microbiología Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal Madrid Spain

Zobrazit více v PubMed

Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2:527–538. doi: 10.1016/S2213-2600(14)70132-8. PubMed DOI

Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672. doi: 10.1056/NEJMoa1105185. PubMed DOI PMC

McCormick J, Mehta G, Olesen HV, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010;375:1007–1013. doi: 10.1016/S0140-6736(09)62161-9. PubMed DOI

Burgel PR, Bellis G, Olesen HV, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015;46:133–141. doi: 10.1183/09031936.00196314. PubMed DOI

Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J. 2007;29:522–526. doi: 10.1183/09031936.00099506. PubMed DOI

Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. 2003;123:20–27. doi: 10.1378/chest.123.1.20. PubMed DOI

Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centers specialising in cystic fibrosis: cross sectional study. BMJ. 1998;316:1771–1775. doi: 10.1136/bmj.316.7147.1771. PubMed DOI PMC

Conway S, Balfour-Lynn IM, De Rijcke K, et al. European Cystic Fibrosis Society standards of care: framework for the cystic fibrosis center. J Cyst Fibros. 2014;13(Suppl 1):S3–S22. doi: 10.1016/j.jcf.2014.03.009. PubMed DOI PMC

Eichinger M, Heussel CP, Kauczor HU, Tiddens H, Puderbach M. Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease. J Magn Reson Imaging. 2010;32:1370–1378. doi: 10.1002/jmri.22374. PubMed DOI

Renz DM, Scholz O, Bottcher J, et al. Comparison between magnetic resonance imaging and computed tomography of the lung in patients with cystic fibrosis with regard to clinical, laboratory, and pulmonary functional parameters. Investig Radiol. 2015;50:733–742. doi: 10.1097/RLI.0000000000000178. PubMed DOI

Wielputz MO, Puderbach M, Kopp-Schneider A, et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med. 2014;189:956–965. doi: 10.1164/rccm.201309-1659OC. PubMed DOI

Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific advisory group, investigators, and coordinators of the epidemiologic study of cystic fibrosis. Chest. 1999;116:639–646. doi: 10.1378/chest.116.3.639. PubMed DOI

FitzPatrick MEB, Bilton D, Perrin F, Westaby D, Simmonds NJ. 245 A 10-year retrospective study of cystic fibrosis patients with distal intestinal obstruction syndrome (DIOS) J Cyst Fibros. 2013;12:S111. doi: 10.1016/S1569-1993(13)60386-0. DOI

Houwen RH, van der Doef HP, Sermet I, et al. Defining DIOS and constipation in cystic fibrosis with a multicenter study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010;50:38–42. doi: 10.1097/MPG.0b013e3181a6e01d. PubMed DOI

Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med. 2013;1:164–174. doi: 10.1016/S2213-2600(13)70025-0. PubMed DOI

Quittner AL, Abbott J, Georgiopoulos AM, et al. International Committee on Mental Health in Cystic Fibrosis: cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax. 2016;71:26–34. doi: 10.1136/thoraxjnl-2015-207488. PubMed DOI PMC

Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014;69:1090–1097. doi: 10.1136/thoraxjnl-2014-205983. PubMed DOI

Zhou J, Garber E, Desai M, Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol. 2006;44:1547–1549. doi: 10.1128/JCM.44.4.1547-1549.2006. PubMed DOI PMC

Pihet M, Carrère J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—a review. Med Mycol. 2009;47:387–397. doi: 10.1080/13693780802609604. PubMed DOI

Liu JC, Modha DE, Gaillard EA. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J Cyst Fibros. 2013;12:187–193. doi: 10.1016/j.jcf.2013.02.003. PubMed DOI

Masoud-Landgraf L, Badura A, Eber E, et al. Modified culture method detects a high diversity of fungal species in cystic fibrosis patients. Med Mycol. 2014;52:179–186. PubMed

Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS ONE. 2014;9:e98502. doi: 10.1371/journal.pone.0098502. PubMed DOI PMC

Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2000;16:464–471. doi: 10.1034/j.1399-3003.2000.016003464.x. PubMed DOI

Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1765–1778. doi: 10.1111/cea.12595. PubMed DOI

Kondori N, Gilljam M, Lindblad A, et al. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. J Clin Microbiol. 2011;49:1004–1009. doi: 10.1128/JCM.01899-10. PubMed DOI PMC

Kondori N, Lindblad A, Welinder-Olsson C, Wenneras C, Gilljam M. Development of IgG antibodies to Exophiala dermatitidis is associated with inflammatory responses in patients with cystic fibrosis. J Cyst Fibros. 2014;13:391–399. doi: 10.1016/j.jcf.2013.12.007. PubMed DOI

Hickey PW, Sutton DA, Fothergill AW, et al. Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol. 2009;47:3091–3097. doi: 10.1128/JCM.00460-09. PubMed DOI PMC

Hirschi S, Letscher-Bru V, Pottecher J, et al. Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol. 2012;50:4168–4170. doi: 10.1128/JCM.01928-12. PubMed DOI PMC

Martinez Muniz FB, Martinez Redondo M, Prados Sanchez C, Garcia Rodriguez J. Chronic lung infection caused by Trichosporon mycotoxinivorans and Trichosporon mucoides in an immunocompetent cystic fibrosis patient. Arch Bronconeumol. 2016;52:400. doi: 10.1016/j.arbres.2015.11.013. PubMed DOI

Shah AV, McColley SA, Weil D, Zheng X. Trichosporon mycotoxinivorans infection in patients with cystic fibrosis. J Clin Microbiol. 2014;52:2242–2244. doi: 10.1128/JCM.03309-13. PubMed DOI PMC

Rainer J, Kaltseis J, de Hoog SG, Summerbell RC. Efficacy of a selective isolation procedure for members of the Pseudallescheria boydii complex. Antonie Van Leeuwenhoek. 2008;93:315–322. doi: 10.1007/s10482-007-9206-y. PubMed DOI

De Hoog GS, Haase G. Nutritional physiology and selective isolation of Exophiala dermatitidis. Antonie Van Leeuwenhoek. 1993;64:17–26. doi: 10.1007/BF00870917. PubMed DOI

Haase G, Skopnik H, Groten T, Kusenbach G, Posselt HG. Long-term fungal cultures from sputum of patients with cystic fibrosis. Mycoses. 1991;34:373–376. doi: 10.1111/j.1439-0507.1991.tb00797.x. PubMed DOI

Hogardt M, Ulrich J, Riehn-Kopp H, Tummler B. EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates. J Clin Microbiol. 2009;47:3435–3438. doi: 10.1128/JCM.01182-09. PubMed DOI PMC

Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2001;18:298–305. doi: 10.1183/09031936.01.00068901. PubMed DOI

Baxter CG, Moore CB, Jones AM, Webb AK, Denning DW. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest. 2013;143:1351–1357. doi: 10.1378/chest.12-1363. PubMed DOI

Gammelsrud KW, Sandven P, Hoiby EA, et al. Colonization by Candida in children with cancer, children with cystic fibrosis, and healthy controls. Clin Microbiol Infect. 2011;17:1875–1881. doi: 10.1111/j.1469-0691.2011.03528.x. PubMed DOI

Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008;7:123–127. doi: 10.1016/j.jcf.2007.06.006. PubMed DOI

Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol. 2016;54:781–786. doi: 10.1093/mmy/myw035. PubMed DOI

Montagna MT, Barbuti G, Paglionico F, et al. Retrospective analysis of microorganisms isolated from cystic fibrosis patients in Southern Italy, 2002–2010. J Prev Med Hyg. 2011;52:209–214. PubMed

Nagano Y, Elborn JS, Millar BC, et al. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol. 2010;48(Suppl 1):S166–S176. doi: 10.3109/13693780903127506. PubMed DOI

Sedlacek L, Graf B, Schwarz C, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros. 2015;14:237–241. doi: 10.1016/j.jcf.2014.12.014. PubMed DOI

Cimon B, Carrère J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000;19:53–56. doi: 10.1007/s100960050011. PubMed DOI

Rougeron A, Schuliar G, Leto J, et al. Human-impacted areas of France are environmental reservoirs of the Pseudallescheria boydii/Scedosporium apiospermum species complex. Environ Microbiol. 2015;17:1039–1048. doi: 10.1111/1462-2920.12472. PubMed DOI

Zouhair R, Rougeron A, Razafimandimby B, et al. Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fibrosis. Med Mycol. 2013;51:603–613. doi: 10.3109/13693786.2013.770606. PubMed DOI

Horré R, Schaal KP, Siekmeier R, et al. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration. 2004;71:360–366. doi: 10.1159/000079640. PubMed DOI

Lebecque P, Leonard A, Huang D, et al. Exophiala (Wangiella) dermatitidis and cystic fibrosis—prevalence and risk factors. Med Mycol. 2010;48(Suppl 1):S4–S9. doi: 10.3109/13693786.2010.495731. PubMed DOI

Matos T, Cerar T, Praprotnik M, Krivec U, Pirs M. First recovery of Rasamsonia argillacea species complex isolated in adolescent patient with cystic fibrosis in Slovenia—case report and review of literature. Mycoses. 2015;58:506–510. doi: 10.1111/myc.12340. PubMed DOI

De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. 2014;13:403–409. doi: 10.1016/j.jcf.2013.12.003. PubMed DOI

Green DM, McDougal KE, Blackman SM, et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res. 2010;11:140. doi: 10.1186/1465-9921-11-140. PubMed DOI PMC

Chaudhary N, Datta K, Askin FB, Staab JF, Marr KA. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med. 2012;185:301–310. doi: 10.1164/rccm.201106-1027OC. PubMed DOI PMC

Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60:703–712. doi: 10.1093/cid/ciu944. PubMed DOI PMC